Kalaris Therapeutics, Inc. Total Liabilities
Kalaris Therapeutics, Inc. total liabilities. Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) has total liabilities worth $41.25 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Kalaris Therapeutics, Inc. (KLRS) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kalaris Therapeutics, Inc. (2018–2025)
Total liabilities of Kalaris Therapeutics, Inc. from 2018 to 2025. This chart illustrates how Kalaris Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore Kalaris Therapeutics, Inc. (KLRS) long-term investment share to see how much of total assets are deployed in long-term investments.
Kalaris Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Kalaris Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Analabs Resources Bhd
KLSE:7083
|
Malaysia | RM305.62 Million |
|
Mereo BioPharma Group PLC ADR
NASDAQ:MREO
|
USA | $6.06 Million |
|
SIL Investments Limited
NSE:SILINV
|
India | Rs-26.30 Billion |
|
Tritax Big Box REIT plc
LSE:BBOX
|
UK | GBX2.82 Billion |
|
Promateris SA
RO:PPL
|
Romania | RON118.86 Million |
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
USA | $16.61 Million |
|
Sinil Pharmaceutical Co. Ltd
KQ:012790
|
Korea | ₩18.23 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Kalaris Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kalaris Therapeutics, Inc. total assets.
Liquidity & Leverage Metrics
Kalaris Therapeutics, Inc. Total Liabilities Ratios Explained
Kalaris Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kalaris Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kalaris Therapeutics, Inc. (2018–2025)
The table below shows the annual total liabilities of Kalaris Therapeutics, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $42.92 Million | +719.28% |
| 2024-12-31 | $5.24 Million | -89.16% |
| 2023-12-31 | $48.35 Million | +41.49% |
| 2022-12-31 | $34.17 Million | -44.28% |
| 2021-12-31 | $61.33 Million | +245.37% |
| 2020-12-31 | $17.76 Million | -0.23% |
| 2019-12-31 | $17.80 Million | +376.26% |
| 2018-12-31 | $3.74 Million | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more